A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: Implications for antibiotic stewardship programs

Pharmacotherapy

Volumn 32, Issue 2, 2012, Pages 129-134

  Le, Frank ^a   Arora, Vaneet ^a,b   Shah, Dhara N ^a,b   Salazar, Miguel ^a   Palmer, Hannah R ^a   Garey, Kevin W ^a,b,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clostridium difficile; Cohort study; Disease severity; Metronidazole; Oral vancomycin

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE PLANNING; RELAPSE; RETROSPECTIVE STUDY; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG EVALUATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 84864602278     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1002     Document Type: Article

References (25)

1. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40.
2. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
3. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
4. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
5. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037-42.
6. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
7. Salazar M, Baskin L, Garey KW, DuPont HL. Clostridium difficile- related death rates in Texas 1999-2005. J Infect 2009; 59:303-7.
8. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
9. Salazar M, Garey KW, Jiang ZD, Dao-Tran T, Dupont H. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci 2009;31:565-71.
10. Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8:555-64.
11. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridiumdifficile- associated diarrhoea and colitis. Lancet 1983;2:1043-6.
12. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90.
13. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10.
14. Louie T, Gerdsom M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium difficile associated diarrhea (CDI). Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17-20, 2007, abstract.
15. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
16. Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010;51:1406-10.
17. Barbut F, Kajzer C, Planas N, Petit JC. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993;31:963-7.
18. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008;47: 56-62.
19. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee. Emerg Infect Dis 1995;1:66.
20. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403-6.
21. Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis 2009;11:467-70.
22. Traynor K. Fidaxomicin approved for C. difficile infections. Am J Health Syst Pharm 2011;68:1276.
23. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
24. Lawrence SJ, Dubberke ER, Johnson S, Gerding DN. Clostridium difficile-associated disease treatment response depends on definition of cure. Clin Infect Dis 2007;45:1648; author reply 9-51.
25. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008;46:1493-8.